Alex Berenson – Revolver News – December 13th…
“This morning, Pfizer disappointed investors by saying it expects sales of its mRNA Covid jab to plunge again in 2024. Annual sales of Pfizer’s shot and anti-Covid drug Paxlovid will fall 35 percent next year – on the heels of an 80 percent collapse this year.
The announcement is an embarrassment for Pfizer executives, marking the third time in only three months they have had to rachet down expectations for Covid sales.
[…]
The fall comes despite a clever ad campaign [with] Kelce, the Kansas City Chiefs tight end (now best-known as Taylor Swift’s beau).
Kelce’s “two things at once” spot encourages people to take both flu and Covid jabs at the same doctor’s visit – unsubtly linking the mRNAs with old-style inactivated virus flu shots, which have far fewer side effects.
But would-be recipients have not been fooled. While mRNA demand has collapsed, demand for flu shots remains solid (despite strong evidence of their uselessness).”
As I noted in the header, Pfizer stock has been dropping like a rock, sitting at $26.63 as of Dec. 15th – the last time shares fell this low for the company was March of 2013 which, to me, seems like it’s not getting as much coverage as it deserves. I haven’t seen anyone pointing out just how catastrophic it seems to be for the pharmaceutical juggernaut:
Historical daily share price chart and data for Pfizer since 1972 adjusted for splits and dividends.
The latest closing stock price for Pfizer as of December 15, 2023 is 26.63.
- The all-time high Pfizer stock closing price was 56.72 on December 16, 2021.
- The 52-week high stock price is 52.16, which is 95.9% above the current share price.
- The 52-week low stock price is 25.76, which is 3.3% below the current share price.
Is that clear enough?
Nearly an all time low.
“[…] earnings and revenue are underperforming as the company struggles through the collapse of the Covid-19 market. Pfizer said Wednesday it expects a combined $8 billion in revenue from its Covid-19 products in 2024, below the FactSet analyst consensus estimate of $13.8 billion.
By midday Wednesday, speculation about whether the company might seek to replace CEO Albert Bourla after next year set in. In an email to investors, Mizuho healthcare equity strategist Jared Holz wrote that it “could be time for new leadership.”
[…]
In its announcement, Pfizer said it expects adjusted diluted earnings of between $2.45 and $2.65 a share in 2024, not including impacts from Seagen. Wall Street analysts had expected significantly higher earnings of $3.17 per share.
[…]
Beneath the mismatch in revenue expectations was what appears to be a broad gap between where the company sees the Covid-19 vaccine and therapeutic market headed, and where investors expect it to go. Pfizer’s revenue guidance for sales of its Covid-19 products is billions of dollars below the FactSet estimate.
On an investor call Wednesday morning, Bourla called the Covid-19 projections “realistic and conservative.”
“We want to be reliable so that we will not create uncertainty, which was the case unfortunately this year,” [he] said.
Shares of Pfizer’s Covid vaccine competitor Moderna fell 4.5% following the news.
[…]
Moderna said in early Nov. that it expects product sales of $4 billion in 2024, which was short of the FactSet analyst consensus estimate of $6 billion at the time. Bancel told Barron’s the company will stand by that guidance.
Moderna said in November that its Covid vaccine market share in the U.S. was 45% in 2023, up from 36% in 2022.
Seems the scamdemic isn’t working out quite as well as they’d hoped…
The truth matters – if you agree please consider subscribing (FREE). Am also on Minds, Gettr, Twitter, Gab, MeWe, Bitchute, Rumble, Odysee, and Clouthub. Any folks generous enough to support the flow of info can donate here. ✌🐸
Modern Republican 
Thanks for sharing this idea Anita
LikeLiked by 1 person